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CUAs has accelerated in recent years. Use of recommended
methods has increased, although a sizeable number of analyses
still do not adhere to best practice. Continued monitoring of
these trends is crucial to enhancing the quality of the ﬁeld.
MC2
15DS—A NEW DYNAMIC QUALITY OF LIFE TOOL WITH
INCREASED SENSITIVITY AND IMPROVED COMPOSITE
STRUCTURE FOR RECALL BIAS AND RESPONSE SIFT
ADJUSTMENTS
Soini EJ1, Ryynänen OP2
1Department of Health Policy and Management, Department of
Social Pharmacy, University of Kuopio, Kuopio, Finland, 2General
Practice, Department of Public Health and Clinical Nutrition,
University of Kuopio, Kuopio, Finland
OBJECTIVES: Response sift (RS) and recall bias (RB) cause
problems in patient-reported outcomes (PRO). RS refers to the
change of meaning in health-related quality of life (HRQoL) in
pretest-posttest design. RB is the result of variation in the recall
of earlier HRQoL states, satisfaction and symptoms. To present
a new composite HRQoL tool for integrating contemporaneous
items with recall/response items. The innovative aim of the
generic 15Ds tool is the adjustment of RB/RS. METHODS: The
widely utilized 15D tool yields both 15-dimensional health pro-
ﬁles and an overall HRQoL index. The 15D was promoted by
the WHO health deﬁnition and the additive valuation of multi-
attribute utility theory (MAU) to produce quality-adjusted life
years (QALY). The 15Ds was innovated by the literature and
pragmatic experience with the 15D. RESULTS: The 15Ds con-
tains 15 contemporary dimensions with ﬁve states (i.e. the con-
ventional 15D), 15 recall/response dimensions with six states for
transitions, and three validation dimensions. The recall/response
dimensions adjust subjects’ contemporary states for RB/RS. The
validation dimensions contain a comparison of the subject’s
general health state to the health of a same-age population (5
states), RB/RS comparison for health transitions (6 states), and
comparison for the level of healing (illness conceptualization, 5
states). A preliminary analysis revealed that patients have more
sensitivity for changes measured as the recall/response items than
for changes in the contemporary items over time. The 15Ds gives
slightly better outcomes in the index changes and offers higher
discrimination for the changes of HRQoL when compared with
the conventional 15D. CONCLUSIONS: The 15Ds can produce
15-dimensional contemporary health proﬁles, 15-dimensional
recall/response health proﬁles, overall HRQoL index for both
15Ds and 15D, and approximations for the validation of tran-
sitions, health and illness. The 15Ds is recommended for recall
(e.g. acute conditions when no baseline HRQoL is obtainable)
and RB/RS adjustment.
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OBJECTIVES: In previous work, we explored through com-
puter-aided simulated clinical trials how heterogeneity of base-
line risk can lead to heterogeneity of treatment-effect under a
variety of assumptions. We now explore how heterogeneity of
competing risks affect treatment-effect heterogeneity under a
variety of assumptions. METHODS: Using simulated clinical
trials in which the intervention has a constant effect on disease-
speciﬁc risk (odds ratio = 0.7) but no effect on competing risk
and in which outcomes in individuals are determined by varying
2 parameters: (1) the overall risk of the outcome of interest and
(2) the ratio between the competing risk and the disease-speciﬁc
(i.e. treatment-responsive) risk. RESULTS: Under conditions in
the simulations, the odds ratio of the treatment-effect on the
overall outcome is highly dependent on the ratio of the compet-
ing and disease-speciﬁc risk, decreasing as this ratio increases.
Although the absolute treatment-effect increases with increasing
overall risk, the odds ratio for the treatment decreases as the
overall risk increases (holding constant the ratio between disease-
speciﬁc and competing risk). When disease-speciﬁc outcomes are
measured, a similar relationship between treatment-effect and
overall risk is observed, although the decrease in the odds ratio
with increasing risk is greatly attenuated. Detecting signiﬁcant
treatment-effect heterogeneity (on the odds ratio scale) based on
competing risk is likely to occur only when competing risk is
very high or when patients can be sub-grouped by variables
which distinguish between disease-speciﬁc and competing risk.
CONCLUSION: The ratio of competing risk to disease-speciﬁc
risk in a population can have an important impact on the mea-
sured treatment effect, even when disease-speciﬁc outcomes are
measured. Detection of competing-risk-based treatment-effect
heterogeneity may depend on the identiﬁcation of risk factors
that differentiate disease-speciﬁc from competing risk. Simula-
tions can be useful to anticipate the magnitude of these effects
when planning a clinical trial.
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OBJECTIVES: The recommendation of the US Panel to incor-
porate productivity costs in terms of health effects (QALYs) in a
cost-effectiveness analysis aroused quite some debate. A crucial
yet under-explored question in this debate is whether people
include effects of ill-health on income in health state valuations
(HSV). The same holds for the actual inclusion in HSV of the
effects of ill-health on leisure. This study aims to test whether
respondents to health-state valuations using TTO questions
include the effects of ill-health on income and leisure when the
measure is silent on both. Moreover, it tests the consequences of
explicit instructions to either include or exclude the income-
effects in HSV. METHODS: Three questionnaires were devel-
oped and administered among the general public. Respondents
were asked to value three distinct EQ-5D health-states using
TTO. In version 1 respondents did not receive instructions on
including or excluding income-effects in their valuations, but
inclusion was assessed afterwards. In versions 2 and 3 respon-
dents were instructed upfront to incorporate income-effects or
to assume that income would not change. They were further-
more asked whether they included the effects of ill-health on
leisure-time in their HSV. RESULTS: In version 1 64% of the
respondents spontaneously included income-effects in their HSV.
In version 2 and 3 88% included leisure-time. There were no dif-
ferences in the valuations of respondents including or excluding
income-effects, also in case of explicit instruction. Inclusion of
leisure-time resulted in a signiﬁcantly lower TTO-value in only
one of the three health-states. CONCLUSIONS: Respondents do
not consistently include income- and leisure-effects in their val-
uations. Including income-effects (spontaneously or instructed)
does not seem to affect TTO-valuations and may therefore best
be placed on the cost-side of the cost-effectiveness ratio. Leisure-
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time may be more inﬂuential, but more research is needed to
ensure appropriate consideration and valuation of leisure.
PATIENT REPORTED OUTCOMES
PR1
HEALTH RELATED QUALITY OF LIFE IN DIFFERENT STATES
OF BREAST CANCER
Lidgren M1,Wilking N1, Jönsson B2, Rehnberg C1
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OBJECTIVES: The aim of this study was to describe the health
related quality of life (HRQoL) in different breast cancer disease
states using preference-based measures. METHODS: A total of
361 consecutive breast cancer patients attending the breast
cancer outpatient clinic at Karolinska University hospital Solna
for outpatient visits between April and May 2005 were included
in the study. The EQ-5D self classiﬁer and a direct Time Trade
Off (TTO) question was used to estimate the HRQoL in differ-
ent breast cancer disease states. RESULTS: All of the different
disease states had lower HRQoL compared to the general pop-
ulation. Patients in their ﬁrst year after a primary breast cancer
had a mean EQ-5D index value of 0.696 (95% conﬁdence 
interval (CI): 0.634–0.747)). Patients in their ﬁrst year after a
recurrence had a mean EQ-5D index value of 0.779 (CI:
0.700–0.849). Patients whom had not had a primary breast
cancer diagnosis or a recurrence during the previous year had a
mean EQ-5D index value of 0.779 (CI: 0.745–0.811). Patients
with metastatic disease reported the lowest HRQoL values, and
had a mean EQ-5D index value of 0.685 (CI: 0.620–0.735). The
main driver behind the reduction in HRQoL was pain and dis-
comfort as well as anxiety and depression. TTO values were
higher for all diseases states compared to the EQ-5D index
values. CONCLUSION: This study shows that breast cancer is
associated with a reduction in HRQoL. This effect is most pro-
nounced for patients with metastatic disease. Our results also
indicate that breast cancer has a permanent negative effect on
HRQoL, even if the patient remains recurrence free.
PR2
ESTIMATING UTILITY VALUES FOR HEALTH STATUS USING
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OBJECTIVES: A new utility index derived of the SF-36, the SF-
6D, was recently developed and has generated an increasing
research in different groups of patients and has also been com-
pared with other utility measures, as it is the EQ-5D. The
purpose of the present work is to validate this index in the
Spanish version of SF-36 with respect to the Spanish version of
the EQ-5D. METHODS: A total of 1843 complete measures of
the SF-36 (version 2) and the EQ-5D (5 items and visual ana-
logic scale-VAS) from 1283 patients who received a solid organ
transplant (kidney, liver, heart or lung) were used. Data were col-
lected at different moments during the ﬁrst year after the surgery
in the context of the Spanish Research Network on Transplan-
tation. SF-6D values were calculated using the model proposed
by its creator. EQ-5D values were calculated using Spanish VAS
tariff (VAS-t) and time-trade off tariff (TTO-t). Spearman corre-
lation coefﬁcients were calculated between SF-6D and EQ-5D
values. RESULTS: Mean value (SD) of SF-6D was 0.67 (0.15)
(range 0.3–1.0), of EQ-5D VAS-t, 0.69 (0.24) (range −0.08–1.0)
and of TTO-t, 0.70 (0.32) (range −0.7–1). Percentage of subjects
scoring the maximum was 1.1% for SF-6D, and 24.5% for the
EQ-5D. SF-6D values had moderate correlation with EQ-5D
VAS-t (r = 0.734) and EQ-5D TTO-t (r = 0.731) (both p < 0.001).
CONCLUSIONS: The SF-6D index derived from the Spanish
version of SF-36 seem to be a valid utility index to be used with
the SF-36 databases from studies made in Spain. However the
moderate correlation between both utility measures indicates
that probably they partially measure different concepts.
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LOW ADHERENCE WITH GASTROPROTECTIVE AGENTS
WHEN CO-PRESCRIBED WITH NSNSAIDS ASSOCIATED WITH
INCREASING RISK OF GI-RELATED HOSPITALISATION
Koncz T, Lister S, Makinson G
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OBJECTIVE: Lack of adherence with gastroprotective agents
(GPAs) when prescribed with non-selective (ns) NSAIDs may
increase risk of hospitalisation for gastrointestinal (GI) condi-
tions. This study assessed the effect of frequent nsNSAID use
with varying levels of GPA use on GI outcomes. METHODS:
Prescription data from a primary care database (DIN-LINK),
representative of the UK population, containing records of over
800,000 patients, was used. Patients with osteoarthritis and/or
rheumatoid arthritis who received nsNSAID therapy and co-
prescribed GPA between September 2003 and August 2005 
were identiﬁed. Adherence (proportion of days covered (%)) at
monthly intervals was deﬁned as days on gastroprotective
therapy within a moving window of three consecutive months
on nsNSAID. Patients were assessed according to their level of
GPA use (0–19, 20–39, 40–59, 60–79, 80–99, 100%). Records
of hospitalisation for GI conditions (also available in the data-
base) at monthly intervals were analysed as a function of GPA
adherence. Odds ratios of GI-related hospitalisation between
cohorts of varying GPA use were calculated. Additional analysis
was performed according to GI risk factors. RESULTS: The data-
base identiﬁed 15,956 patients with an NSAID prescription for
at least 75% of the examined period, and of these, 8890 patients
with a GPA co-prescription with at least 20% use. The rate of
GI-related hospitalisation for the deﬁned period was 2.49% with
full (100%) GPA use. The odds ratio for GI related hospitalisa-
tion of the sub-cohorts vs. that with 100% adherence (95% 
CI), in decreasing order according to adherence, was 1.57
(1.14–2.16), 1.49 (0.95–2.36), 2.85 (1.84–4.43), 3.52
(2.28–5.44), 1.47 (1.19–1.81). The odds of GI-related hospital-
isation were up to 3.5 times higher for NSAID users with poorer
GPA adherence. CONCLUSION: Analysis of observational clin-
ical and prescription data revealed that the lower the GPA use
of frequent NSAID users, the higher the rates of hospitalisation
for GI conditions.
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PREFERENCES OF PEOPLE WITH DIABETES FOR INHALED
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OBJECTIVE: To elicit single-index preferences from people 
with diabetes for treatment with inhaled insulin compared to
injectable insulin. METHODS: Written descriptions were devel-
oped for ﬁve clinical scenarios in Type 1 and Type 2 diabetes
(T1D and T2D): 1) pre-mixed insulin in T1D; 2) basal-bolus
insulin in T1D; 3) pre-mixed insulin in T2D; 4) oral treatment
in T2D; and 5) oral treatment plus basal insulin in T2D. In each
scenario, adjustment or initiation of insulin treatment was
